Researchers screened a panel of drugs that are already approved for clinical use and identified two drugs that provided effective SARS-CoV-2 suppression: cepharanthine and nelfinavir
Photo credit: Louis Reed on Unsplash
Preclinical experiments show that the drugs cepharanthine and nelfinavir may be effective treatments for COVID-19
While preventative care for COVID-19 has made much noise (with vaccines having rolled out in most countries), the soaring infection rates indicate the need for effective treatments. Using cultured cells to study SARS-CoV-2 infections, researchers at the Tokyo University of Science and other institutions have discovered that the drugs cepharanthine and nelfinavir are effective at combating the virus, with the former preventing the virus from entering cells and the latter preventing the virus from replicating.
COVID-19 continues to claim lives across the world and is infecting millions more. Although several vaccines have recently become available, making significant strides towards preventing COVID-19, what about the treatment of those who already have the infection? Vaccines aren’t 100% effective, highlighting the need — now more than ever — for effective antiviral therapeutics. Moreover, some people can’t receive vaccines due to health issues, and new variants of SARS-CoV-2, the virus that causes COVID-19, that can penetrate vaccine-conferred immunity, are being reported, indicating that we need to think beyond prevention.
Given this need, a team of researchers based in Japan, the US, and the UK launched a project to develop effective therapeutics. This team included several researchers based at Tokyo University of Science: Visiting Professor Koichi Watashi, Dr. Hirofumi Ohashi, Professor Shin Aoki, Professor Kouji Kuramochi, and Assistant Professor Tomohiro Tanaka. Their goal was clear and simple: finding a cure for COVID-19.
To achieve this goal, the researchers first established an experimental system for screening drugs that may help to control infections. This system used a type of cells called VeroE6/TMPRSS2 cells, which were manipulated to efficiently be infected with and produce SARS-CoV-2. “To determine whether a drug of interest could help combat infection by SARS-CoV-2, we simply had to expose VeroE6/TMPRSS2 cells to both the drug and SARS-CoV-2 and then observe whether the drug’s presence served to hinder the virus’s efforts to infect cells,” explains Professor Watashi.
The researchers used this experimental system to screen a panel of drugs that are already approved for clinical use, including drugs like remdesivir and chloroquine that have already being approved or are being trialed as treatments for COVID-19. In an exciting outcome, the researchers found two drugs that provided effective SARS-CoV-2 suppression: cepharanthine, which is used to treat inflammation, and nelfinavir, which is approved for the treatment of HIV infection.
Cepharanthine inhibited the entry of the virus into cells by preventing the virus from binding to a protein on the cell membrane, which it uses as a gateway. In contrast, nelfinavir worked to prevent the virus from replicating inside the cell by inhibiting a protein that the virus relies on for replication. Given that these drugs have distinct antiviral mechanisms, using both of them together could be especially effective for patients, with computational models predicting that combined cepharanthine/nelfinavir therapy can hasten the clearance of SARS-CoV-2 from a patient’s lungs by as few as 4.9 days.
So, does this mean we will be seeing these new drugs in COVID-19 treatment centers? Of course, the drug duo isn’t ready to be rolled out into healthcare systems just yet. These findings justify further research into the clinical potential of cepharanthine/nelfinavir therapy, and only following this can we say for sure that it is useful and helpful.
Nevertheless, given the ongoing nature of the COVID-19 pandemic and the ever-increasing death toll, the development of cepharanthine/nelfinavir therapy may provide clinicians and patients with a much-needed new treatment option.
Original Article: The Dream Team: Scientists Find Drug Duo That May Cure COVID-19 Together
More from: Tokyo University of Science
The Latest Updates from Bing News & Google News
Go deeper with Bing News on:
Cepharanthine and nelfinavir
- Feed has no items.
Go deeper with Google Headlines on:
Cepharanthine and nelfinavir
Go deeper with Bing News on:
Treatments for COVID-19
- WA expands telehealth options to improve access to COVID treatment
Washington residents who test positive for the coronavirus can now get a free telehealth appointment for treatment consultation, regardless of their insurance coverage.
- Concerned about COVID-19?
President Joe Biden is set to name top officials from the Federal Emergency Management Agency and the Centers for Disease Control and Prevention to serve as the White House coordinators ...
- Doctor discusses President Biden's rebound COVID-19
President Biden is back in isolation after experiencing what his doctor describes as a rebound COVID-19 infection. One Newnan physician explains what happened, and why people shouldn't panic.
- What is the difference between COVID-19 reinfection, rebound?
When it comes to COVID-19, there are two things doctors are keeping an eye on right now: viral rebound and reinfection. This is after President Joe Biden went back ...
- What are the major differences between the monkeypox and COVID-19 outbreaks?
After more than two years dealing with a pandemic, news of year another viral outbreak can seem overwhelming. As COVID-19 continues to circulate, we should also be vigilant about monkeypox, though ...